source
- Novo’s IL-6 inhibitor ziltivekimab may target milder cardio-renal patients after Phase 3 missAt the American Heart Association meeting, investigators discussed new data on Novo Nordisk’s IL-6 inhibitor ziltivekimab, suggesting it could be studied in patients with less severe cardiovascular…
- FDA cuts required analytical tests for emergency-use diagnostic devices in new guidanceOn 9 November 2026 the U.S. Food and Drug Administration released final guidance aimed at simplifying validation of in-vitro diagnostic devices used in public-health emergencies. The document outli…